Regulating Human Embryonic Stem Cell in China

En savoir plus sur le livre

Focusing on the patentability and ethical concerns surrounding human embryonic stem cell research, the book examines the prevalence of fraudulent and unsafe therapies, particularly in China, where oversight is lacking. It critiques the inefficacy of current patent and funding controls in regulating this field. Ultimately, the author advocates for a new regulatory framework in China, suggesting that research should be governed under a reconciled international regime to ensure ethical practices and safety in human embryonic stem cell research.